Quince Therapeutics (QNCX) Non-Current Debt (2023 - 2025)

Quince Therapeutics has reported Non-Current Debt for 3 years, with the latest figure at $17.0 million in Q2 2025.

• On a quarterly basis, Non-Current Debt rose 22.81% year-over-year to $17.0 million in Q2 2025; TTM through Jun 2025 was $17.0 million, a 22.81% increase from a year earlier, with the FY2024 full-year figure at $14.3 million, up 6.64% from the prior year.
• Non-Current Debt was $17.0 million for Q2 2025 at Quince Therapeutics, up from $15.3 million in the prior quarter.
• The five-year high for Non-Current Debt was $17.0 million in Q2 2025, with the low at $13.4 million in Q4 2023.
• Average Non-Current Debt over 3 years is $14.6 million, with a median of $14.3 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt grew 6.64% in 2024, then grew 22.81% in 2025.
• Over 3 years, Non-Current Debt stood at $13.4 million in 2023, then advanced by 6.64% to $14.3 million in 2024, then gained by 18.63% to $17.0 million in 2025.
• The last three Non-Current Debt figures came in at $17.0 million (Q2 2025), $15.3 million (Q1 2025), and $14.3 million (Q4 2024), per Business Quant data.